Evotec's High-Stakes Pivot: Can a Fire Sale of Assets Outrun the Cash Burn?
Published on 07/29/2026 at 17:32 | Redaktion boerse-global.de
The Hamburg-based drug discovery specialist is walking a tightrope that grows thinner by the trading session. Evotec's stock, now changing hands at roughly €3.49, sits barely 9% above its 52-week nadir of €3.19 — a floor that was tested just two weeks ago. With the shares down 36% since January and more than halved over the past twelve months, the company's market capitalization has shriveled to around €615 million. The question hanging over the stock is no longer about growth trajectory but about survival mechanics: can CEO Christian Wojczewski's restructuring plan generate enough momentum before the company's cash reserves are consumed by operational losses?
The immediate catalyst for the sell-off is well understood. Evotec slashed its full-year guidance, abandoning hopes of profitability in 2026 and now forecasting an adjusted loss. The culprit was a familiar one: milestone payments that failed to materialize and sluggish new business in the research services division. The market's response was brutal — nearly 30% wiped off the share price in a single month — reflecting not just disappointment with the numbers but a deeper erosion of trust in management's ability to forecast its own business.
Wojczewski's answer to the crisis is the "Horizon" program, a restructuring effort that goes far beyond typical cost-cutting. The plan calls for eliminating up to 800 positions and shrinking Evotec's global footprint to just ten sites. The strategic pivot is toward an "asset-light" model that sheds capital-intensive manufacturing capabilities in favor of a sharper focus on early-stage drug research. But such transformations are expensive and time-consuming, and the market is impatient.
To bridge the gap, Evotec has been selling off prized assets. The disposal of its Toulouse facility to Sandoz closed in December 2025, bringing in roughly $350 million in cash plus potential royalties. The sale of its stake in Tubulis to Gilead in early 2026 added another $100 million. These transactions provided a crucial liquidity injection in the first half of the year, but critics argue they came at a strategic cost. The Toulouse site housed Evotec's J.POD biologics manufacturing platform — a technological differentiator that the company has now surrendered for short-term balance sheet relief.
Should investors sell immediately? Or is it worth buying Evotec?
The financial strain is evident in the operating metrics. First-quarter 2026 revenue slumped to €156.6 million, while adjusted EBITDA swung to negative €21.9 million. Restructuring provisions of €75 million are weighing on results, and the company's cash position stood at €444.8 million at the end of the first quarter — a buffer that will be tested by ongoing operational cash burn.
Technical indicators offer a flicker of hope for the bulls. The relative strength index sits at 28.2, deep in oversold territory that historically precedes a bounce. But many analysts view this signal with skepticism, arguing that fundamental deterioration outweighs any chart-based argument for a recovery. The stock remains well below both its 50-day and 200-day moving averages, keeping the overarching trend firmly negative.
The ownership structure adds another layer of complexity. Financier Triton has built a position approaching 10%, signaling that at least one sophisticated investor sees value at these levels. But strategic holders Novo Holdings and Mubadala control significant stakes and are unlikely to sell at current prices, given that the stock has lost more than half its value from its peak. This standoff between patient long-term holders and a potential activist or acquirer creates an unusual dynamic — the stock is too cheap for some to sell and too risky for most to buy.
Evotec at a turning point? This analysis reveals what investors need to know now.
The next major inflection point comes in August with the release of half-year results. Investors will scrutinize two metrics above all: the trajectory of cash reserves and tangible evidence that Horizon is delivering cost savings. The program targets €75 million in annual savings by the end of 2027, but the market needs to see progress sooner. If the stock can hold above €3.50, a recovery scenario remains plausible. A break below the €3.19 low, however, could trigger another wave of selling, with the psychologically significant €3.00 level coming into view.
For now, Evotec is a battleground stock in the truest sense. Day traders see an oversold bounce opportunity; long-only fund managers see a broken growth story; and private investors who bought at higher levels are nursing painful losses. The company's scientific platform and partnerships with pharmaceutical heavyweights like Bristol Myers Squibb remain valuable, but they are not enough to arrest the decline on their own. What Evotec needs most is something it currently lacks: credibility. Without operational proof that the delayed milestones are merely postponed rather than lost, every argument for owning the stock remains theoretical.
Ad
Evotec Stock: New Analysis - 29 July
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
